Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Transcode Therapeutics Inc
(NQ:
RNAZ
)
0.5499
+0.0249 (+4.74%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
725,735
Open
0.5300
Bid (Size)
0.5352 (31)
Ask (Size)
0.5499 (18)
Prev. Close
0.5250
Today's Range
0.5015 - 0.5760
52wk Range
0.1212 - 6.800
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 15, 2024
Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports 2023 Results; Provides Business Update
April 03, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+240.71%
+240.71%
1 Month
-19.49%
-19.49%
3 Month
-29.50%
-29.50%
6 Month
+52.79%
+52.79%
1 Year
-91.30%
-91.30%
More News
Read More
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
March 28, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Looking Into TransCode Therapeutics's Recent Short Interest
January 29, 2024
Via
Benzinga
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
March 06, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
February 20, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Why Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
February 01, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
February 01, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 31, 2024
Via
Benzinga
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
January 31, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
January 29, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
January 22, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
January 22, 2024
Via
Benzinga
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 19, 2024
Via
Benzinga
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
January 18, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
January 12, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 17, 2024
Via
Benzinga
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
January 11, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
January 04, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
December 12, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
December 05, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
December 04, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
December 01, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.